Physician profile
Mathews John
NPI 1174571574
$5,384.98
in general payments reported to CMS, 2019-2025
29 companies · $1,061 in 2025
The $1,061 reported for 2025 was more than what 82% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $708 · 2020: $644 · 2021: $780 · 2022: $629 · 2023: $518 · 2024: $1,046 · 2025: $1,061.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,348 · Education: $276.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,347.63 |
| Education | $276.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $939.35 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $840.93 | 2019-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $615.50 | 2019-2025 | Rexulti, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $341.23 | 2019-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Alkermes, INC. | $293.31 | 2019-2025 | Aristada, Lybalvi |
| Abbvie INC. | $274.86 | 2021-2024 | |
| Neurocrine Biosciences, INC. | $263.66 | 2019-2025 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $251.42 | 2023-2025 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $208.49 | 2019-2024 | Jornay Pm |
| E.R. Squibb & Sons, L.L.C. | $198.65 | 2024-2025 | Cobenfy |
| Allergan, INC. | $190.85 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $136.92 | 2020-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $132.07 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $131.22 | 2019-2025 | Fanapt |
| Sunovion Pharmaceuticals INC. | $94.55 | 2019-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $76.14 | 2023-2025 | Sunosi, Auvelity |
| Avanir Pharmaceuticals, INC. | $65.59 | 2019-2021 | |
| Noven Therapeutics, LLC | $53.81 | 2021-2025 | Xelstrym, Secuado |
| Idorsia Pharmaceuticals US INC | $44.99 | 2023-2024 | Quviviq |
| Collegium Pharmaceutical, INC. | $43.82 | 2025 | Jornay Pm |
| Indivior INC. | $36.35 | 2019-2020 | |
| Adlon Therapeutics L.P. | $34.47 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $19.82 | 2021 | |
| Owp Pharmaceuticals, INC. | $19.34 | 2024 | Subvenite |
| Almatica Pharma LLC | $18.85 | 2025 | Loreev Xr |
| Corium, LLC | $18.31 | 2023 | Azstarys |
| Tris Pharma INC | $16.27 | 2023 | Dyanavel Xr |
| Bausch Health US, LLC | $12.11 | 2019 | |
| Merck Sharp & Dohme LLC | $12.10 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mathews John listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.